Overview

Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis

Status:
Withdrawn
Trial end date:
1999-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Exisulind may be effective in preventing the development and growth of polyps in patients who have familial adenomatous polyposis. PURPOSE: Randomized phase II/III trial to determine the effectiveness of exisulind in preventing the development and growth of polyps in patients who have familial adenomatous polyposis.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Utah
Collaborator:
National Cancer Institute (NCI)
Treatments:
Sulindac sulfone